



08-14-01

GAU 1641

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 94,784-L)

PATENT

TECH CENTER 1600/2900

AUG 16 2001

RECEIVED

In the Application of:

Stojilkovic et al.

Serial No. 09/665,358

Filing Date: September 19, 2000

For: Novel Bacterial Hemoglobin Receptor
Genes and Uses

Examiner:

Group Art Unit: 1641

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
 - a) Information Disclosure Statement;
 - b) PTO Form 1449 and cited references;
 - c) Return postcard
2. With respect to fees:
 - a) No fee is required at this time.
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage Express Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on August 14, 2001.

Respectfully submitted,

Date: August 14, 2001

Kevin E. Noonan
Registration No. 35,303



#3
DmJ
8-17-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 94,784-L)

RECEIVED
AUG 16 2001
PATENT
TECH CENTER 1600/2900

In the Application of:)	
)	
Stojiljkovic et al.)	Examiner:
)	
Serial No. 09/665,358)	
)	Group Art Unit: 1641
Filing Date: September 19, 2000)	
)	
For: Novel Bacterial Hemoglobin Receptor)	
Genes and Uses)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

RECEIVED

AUG 16 2001

TECH CENTER 1600/2900

United States Patents

Ladner et al., United States Patent No. 5,223,409, issued June 29, 1993

Mullis et al., United States Patent No. 4,683,195, issued July 28, 1987

Mullis et al., United States Patent No. 4,683,202, issued November 27, 1990

Stojiljkovic al., United States Patent No. 6,121,037

Wilding et al., United States Patent No. 5,304,487

Other Documents

Archibald and DeVoe, (1979) FEMS Microbiol. Lett., 6, pp. 159-162

Baggs and Neilands, (1991), Microbiol. Rev., 51, 509-518

Calver et al., (1976) Can. J. Microbiol., 22, 832-838

Cornelissen et al., (1993) J. Bacteriol., 174: pp. 5788-5797

Correia et al., (1988) J. Biol. Chem., 263: 12194-12198

Coulton and Pang, (1983) Curr. Microbiol., 9: pp. 93-98

Dyer et al., (1987) Infect. Immun., 55: pp. 2171-2175

Fenno et al., (1993) Gene, 130: 81-90

Gerlach et al., (1992) Infect. Immun., 60: 3253-3261

Gotschlich et al., (1987) J. Exp. Med., 165: pp. 471-482

Heller et al., (1988) Gene, 64: pp. 147-153

Henderson and Payne, (1994) J. Bacteriol, 176: pp. 3269-3277

Hnatowich et al., (1983) Science, 220: pp. 613-615

Holbien et al., (1981) Infect. Immun., 34: 120-125

- Jarosik et al., (1994) *Infect. Immun.*, 62: pp. 2470-2477
- Kellog et al., (1963) *J. Bacteriol.*, 85: 1274-1279
- Knight et al., (1992) *Mol. Microbiol.*, 6: pp. 1565-1573
- Koebnik et al., (1993) *Trends Microbiol.*, 6: pp. 1565-1573
- Lee and Hill, (1992) *J. Gen. Microbiol.*, 138: 2647-2656
- Lee, (1994) *Microbiol.*, 140: 1473-1480
- Lundrigan & Kadner, (1986) *J. Biol. Chem.*, 261: pp. 10797-10801
- Martek and Lee, (1994) *Infect. Immun.*, 62: 700-703
- Meares et al., (1984) *Anal. Biochem.*, 142: 68-78
- Mickelson et al., (1982) *Infect. Immun.*, 35: pp. 915-920
- Nassif et al., (1993) *Mol. Microbiol.*, 6: pp. 719-725
- Otto et al., (1992) *Crit. Rev. Microbiol.*, 18: 217-233
- Pettersson et al., (1993) *Infect. Immun.*, 61: 4724-4733
- Pettersson et al., (1994) *J. Bacteriol.*, 176: pp. 1764-1766
- Postle, (1990) *Mol. Microbiol.*, 133: pp. 891-898
- Riboli et al., (1991) *Microb. Pathogen.*, 10: pp. 393-403
- Rudinger, (June 1976), *Peptide Hormones*, pp. 1-7
- Saiki et al., (1988) *Science*, 230: 1350-1354
- Schoffler and Braun, *Molec. Gen. Genet.*, 217: pp. 378-383
- Schryvers and Morris, (1988) *Infect. Immun.*, 56: pp. 1144-1149
- Schryvers and Morris, (1988) *Mol. Microbiol.*, 2: 281-288
- Schryvers et al., (1989) *Infect. Immun.*, 57(8): pp.2425-2429

Schryves, (1988) *Mol. Microbiol.*, Vol. 2, pp. 467-472

Stojiljkovic et al., (1995) *Mol. Microbiol.*, 15: pp. 531-541

Stroebner and Payne, (1988) *Infec. Immun.*, 56: pp. 2891-2895

Struyve et al., (1991) *J. Mol. Biol.*, 218: 141-148

Walters, (1993) Pharmaceutical Biotechnology, pp. 165-174

Weinberg. (1984) *Physiological Rev.*, 64: pp. 65-102

West and Sparling, (1985) *Infect. Immun.*, 47: pp. 288-294

Date: August 14, 2001



Respectfully submitted,

Kevin E. Noonan, Ph.D.
Reg. No. 35,303

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 94,784-L	Serial No. 09/665,358
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Stojiljkovic et al.	
		Filing Date: September 19, 2000	Group: 1641

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	1	5,223,409	6/29/93	Ladner et al.			
	2	4,683,195	7/28/87	Mullis et al.			
	3	4,683,202	11/27/90	Mullis et al.			
	4	6,121,037	9/19/00	Stojiljkovic et al.			
	5	5,304,487	4-19-94	Wilding et al.			


OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

6	Archibald and DeVoe, (1979) FEMS Microbiol. Lett., 6, pp. 159-162
7	Baggs and Neilands, (1991), Microbiol. Rev., 51: 509-518
8	Calver et al., (1976) Can. J. Microbiol., 22, 832-838
9	Cornelissen et al., (1993) J. Bacteriol., 174: pp. 5788-5797
10	Correia et al., (1988) J. Biol. Chem., 263: 12194-12198
11	Coulton and Pang, (1983) Curr. Microbiol., 9: pp. 93-98
12	Dyer et al., (1987) Infect. Immun., 55: pp. 2171-2175
13	Fenno et al., (1993) Gene, 130: 81-90
14	Gerlach et al., (1992) Infect. Immun., 60: 3253-3261
15	Gotschlich et al., (1987) J. Exp. Med., 165: pp. 471-482
16	Heller et al., (1988) Gene, 64: pp. 147-153
17	Henderson and Payne, (1994) J. Bacteriol., 176: pp. 3269-3277
18	Hnatowich et al., (1983) Science, 220: pp. 613-615

RECEIVED
 AUG 16 2001
 TECH CENTER 1600/2900

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	Atty. Docket No. 94,784-L	Serial No. 09/665,358
	Applicant: Stojilkovic et al.	
	Filing Date: September 19, 2000	Group: 1641

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.


19	Holbien et al., (1981) Infect. Immun., 34: 120-125		
20	Jarosik et al., (1994) Infect. Immun., 62: pp. 2470-2477		
21	Kellog et al., (1963) J. Bacteriol., 85: 1274-1279		
22	Knight et al., (1992) Mol. Microbiol., 6: pp.1565-1573		
23	Koebnik et al., (1993) Trends Microbiol., 6: pp. 1565-1573		
24	Lee and Hill, (1992) J. Gen. Microbiol., 138: 2647-2656		
25	Lee, (1994) Microbiol., 140: 1473-1480		
26	Lundrigan & Kadner, (1986) J. Biol. Chem., 261: pp. 10797-10801		
27	Martek and Lee, (1994) Infect. Immun., 62: 700-703		
28	Meares et al., (1984) Anal. Biochem., 142: 68-78		
29	Mickelson et al., (1982) Infect. Immun., 35: pp. 915-920		
30	Nassif et al., (1993) Mol. Microbiol., 6: pp. 719-725		
<table border="1"> <tr> <td>Examiner</td> <td>Date Considered</td> </tr> </table>		Examiner	Date Considered
Examiner	Date Considered		

RECEIVED
 AUG 16 2001
 TECH CENTER 1600/2900

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

94,784-L

09/665,358

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant: Stojilkovic et al.

Filing Date: September 19, 2000

Group: 1641

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

31	Otto et al., (1992) Crit. Rev. Microbiol., 18:217-233
32	Pettersson et al., (1993) Infect. Immun., 61: 4724-4733
33	Pettersson et al., (1994) J. Bacteriol 176:pp.1764-1766
34	Postle, (1990) Mol. Microbiol., 133: pp. 891-898
35	Riboli et al., (1991) Microb. Pathogen., 10: pp. 393-403
36	Rudinger, June 1976, Peptide Hormones, pp.1-7
37	Saiki et al., (1988) Science, 230: 1350-1354
38	Schoffler and Braun, Molec. Gen. Genet., 217: pp. 378-383
39	Schryvers and Morris, (1988) Infect. Immun., 56: pp. 1144-1149
40	Schryvers and Morris, (1988) Mol. Microbiol., 2: 281-288
41	Schryvers et al., (1989) Infect. Immun., 57(8): pp.2425-2429
42	Stojilkovic et al., (1995) Mol. Microbiol. 15:pp.531-541
43	Stroebner and Payne, (1988) Infect. Immun., 56: pp. 2891-2895
44	Struyve et al., (1991) J. Mol. Biol., 218: 141-148
45	Walters, (1993) <u>Pharmaceutical Biotechnology</u> , pp. 165-174
46	Weinberg. (1984) Physiological Rev., 64: pp. 65-102
47	West and Sparling, (1985) Infect. Immun., 47: pp. 288-294

RECEIVED
 AUG 16 2001
 TECH CENTER 1600/2900

Examiner

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.